Telix Pharmaceuticals Limited provided earnings guidance for Full year revenue 2024. For the year, company's expected range of revenue to be $445 Million to $465 Million, representing an approximate 35%-40% increase on 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.45 AUD | -0.26% | +2.56% | +53.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.12% | 3.38B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024